/ /

  • linkedin
  • Increase Font
  • Sharebar

    European Commission approves adalimumab for paediatric uveitis

    The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.

    Used for years in rheumatoid arthritis and other autoimmune disorders, the drug gained European approval in May 2016 for use in noninfectious intermediate and posterior uveitis and panuveitis in adult patients who cannot be treated effectively with corticosteroids. It received similar approval in adults in June 2016 from the U.S. Food and Drug Administration (FDA).

    Adalimumab is a fully human anti-tumour necrosis factor-alpha (TNF-alpha) monoclonal antibody. Some research has suggested that the proinflammatory cytokine TNF-alpha plays a role in uveitic inflammation. Its levels in serum and aqueous humour are up-regulated in patients with uveitis.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results